Baxter has settled on a name for its $4.5 billion kidney care division, which is slated to strike out on its own as an independent portfolio of dialysis machines, acute renal therapies and services.

A new day has dawned for people with multiple sclerosis, thanks to the launch of a new app that aims to help them better understand the disease and, in doing so, improve their care.

One-third of patients experienced an adverse event related to Stoke Therapeutics’ Dravet syndrome treatment during a midstage clinical trial, sending shares down 30%.

GE HealthCare has boosted its financial outlook for the remainder of the year—as hospitals have once again begun investing in imaging hardware and services, as well as technologies that aim to help ease the strain of ongoing labor shortages—and has its sights set on new horizons driven by Alzheimer’s disease research.

The squeeze on SQZ Biotechnologies is getting tighter. After 12 months of value destruction, the biotech reported that Roche has dropped its option on a solid tumor program—and that SQZ is assessing strategic alternatives to partner “all its clinical and preclinical assets across all disease areas and indications.”

Another mRNA vaccine for malaria is on the way. This time, its creators are taking a page from the cancer immunotherapy playbook to make it more effective.

Since the start of 2020, BD’s Alaris infusion pumps have been the subject of more than half-a-dozen Class I hardware and software recalls, a handful of cybersecurity warnings and a years-long distribution hold.

Unexpected findings about how cell stress impacts gene expression have brought researchers a step closer to solving one of the many mysteries of cancer metastasis—and, potentially, to new ways to prevent it.

Amgen’s lupus pursuits have encountered another pitfall, this time via potential acquisition of Horizon Therapeutics.

Kodiak Sciences has blamed an “unexpected increase in cataracts” as a reason for the failure of a pair of phase 3 trials that have led the biotech to drop its antibody biopolymer conjugate and halved its share price.